Community consultation program will enable people impacted by cystic fibrosis to provide input, insights and perspectives
Read MoreNews
All media inquiries can be directed to mediarelations@cysticfibrosis.ca or by calling 1-800-378-2233.
Cystic Fibrosis Canada calls on remaining provinces to save lives and list Trikafta immediately
Read MoreCystic Fibrosis Canada applauds Ontario, Alberta, and Saskatchewan for listing Trikafta under public drug benefit programs
Read MoreProvinces pressed to save lives by following guidance from CF clinicians, and fund Trikafta now for all Canadians who can benefit
Read MoreA letter has been sent to the Honourable François Legault, Premier of the Province of Quebec, and Christian Dubé, Minister of Health, regarding the INESSS recommendation for the cystic fibrosis drug, Trikafta.
Read MoreCystic Fibrosis Canada calls on Quebec Health Minister to save lives by instead following the guidelines developed by CF clinicians, and fund Trikafta now for all Quebecers who can benefit...
Read MoreFundraising milestone a reflection of Kin Canada club members’ decades long commitment to the CF community.
Read MoreCystic Fibrosis Canada has published new standardized care guidelines for modulator use in Canada.
Read MoreIf implemented, CADTH’s recommendation for the public funding of Trikafta would see access limited to only some of those who could benefit, requiring people to become sicker before offering treatment.
Read MoreThe Canadian Agency for Drugs and Technologies in Health (CADTH) provided this week short sighted and narrow guidance regarding game changing cystic fibrosis (CF) drug Trikafta, that, if adopted by the provinces, could effectively exclude over 25% of eligible Canadians with cystic fibrosis (CF), many of whom are youth, who could greatly benefit from the drug.
Read More